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Abstract 
One classical feature of cancer cells is their metabolic acquisition of a highly glycolytic 
phenotype. Carbon monoxide (CO), one of the products of the cytoprotective molecule heme 
oxygenase-1 (HO-1) in cancer cells, has been implicated in carcinogenesis and therapeutic 
resistance. However, the functional contributions of CO and HO-1 to these processes are poorly 
defined. In human prostate cancers, we found that HO-1 was nuclear localized in malignant 
cells, with low enzymatic activity in moderately differentiated tumors correlating with relatively 
worse clinical outcomes. Exposure to CO sensitized prostate cancer cells but not normal cells to 
chemotherapy, with growth arrest and apoptosis induced in vivo in part through mitotic 
catastrophe. CO targeted mitochondria activity in cancer cells as evidenced by higher oxygen 
consumption, free radical generation and mitochondrial collapse. Collectively, our findings 
indicated that CO transiently induces an anti-Warburg effect by rapidly fueling cancer cell 
bioenergetics, ultimately resulting in metabolic exhaustion. 
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Introduction 
 Epithelial cancers, including prostate, breast and lung cancer are still leading causes of 
deaths in the US and treatment for advanced disease is limited(1). A standard of first-line care 
for advanced and metastatic cancers remains chemotherapy such as taxols, doxorubicin and 
cisplatin (2). Rapid proliferation of primary tumor and cancer cell survival during spread to 
distant organs as well as resistance to treatment are possible in part due to the remarkable 
metabolic adaptation known as the Warburg effect(3). The Warburg effect is characterized by 
increased glucose uptake and elevated glycolysis with a limited oxygen consumption rate 
(OCR) resulting in lactic acid fermentation(4). High rates of energy consuming processes 
including protein, DNA and fatty acid synthesis in cancer cells is often accompanied by an 
increased oxidative state of dysfunctional mitochondria(5).  The promotion of tumor growth 
requires in part, a selection of cancer cells with repressed mitochondrial activity and 
biogenesis(6). Defects in mitochondrial ROS metabolism from electron transport chains in 
cancer cells have been linked directly to increased cancer cell glucose metabolism. The free 
radical theory of cancer implicates ROS as a principal cause of early mutations as well as being 
involved in the response to treatment(7-11). 
 Heme oxygenases (HO) which degrade heme to biliverdin, carbon monoxide (CO) and 
iron  are critical modulators of metabolism and mitochondrial activity. ,, Expression of HO-1, 
the stress inducible isoform, is strictly regulated while HO-2 is ubiquitously expressed primarily 
in brain and testes. Their functional role in cancer has not been clearly elucidated and remains 
controversial.  HO-1 can impart potent anti-proliferative and proapoptotic effects via antioxidant 
mechanisms as demonstrated in breast and lung cancer cell lines.(12, 13) Better survival rates 
were observed in colorectal cancer patients where HO-1 expression correlated with lower rates 
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of lymphatic tumor invasion. In contrast, overexpression of HO-1 has been shown to accelerate 
pancreatic cancer aggressiveness by increasing tumor growth, angiogenesis and metastasis(14). 
Similar effects were observed in melanoma(15), gastric(16) and renal cancers(17). In prostate 
cancer patients, HO-1 is localized in the nucleus and correlated with cancer progression(18). 
Nuclear HO-1 was also detected in head and neck squamous carcinomas and associated with 
tumor progression(19). Recently, nuclear HO-1 has been linked to resistance to Imatinib in 
chronic myeloid leukemia(20). Further evidence for HO-1 in cancer incidence presides in the 
identification of a GT length polymorphism of the HO-1 promoter that is highly correlative with 
cancer severity(21).  Individuals with long GT repeats in the HO-1 promoter and associated low 
expression of HO-1 showed a higher frequency of gastric or lung adenocarcinoma and oral 
squamous cancer versus those with short GT repeats and higher HO-1 expression(22). CO, 
biliverdin, bilirubin as well as iron and ferritin serve as potential modulators of tumorigenesis 
however all have been minimally studied in cancer(23),.  
In the present studies, we first performed a detailed analysis of a large cohort of prostate 
cancer patients and confirmed HO-1 nuclear localization in moderately advanced tumors where 
it is enzymatically inactive and therefore may be a critical regulator of cancer progression. We 
tested the hypothesis that HO-1, through its ability to generate CO, modulates cancer cell 
growth in vitro and in vivo using human and murine prostate and lung cancer models. 
Paradoxically, CO rapidly enhanced mitochondria activity of cancer cells that results in 
metabolic exhaustion and cellular collapse causing tumor regression. Further, CO increased 
cancer cell sensitivity to chemotherapeutics one thousand fold while simultaneously protecting 
normal cell growth and viability.  
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Materials and Methods 
PCa samples & Tissue microarray 
Benign and malignant samples of 482 patients undergoing radical prostatectomy for localized 
PCa were subjected in duplicate to tissue microarray (TMA) constructs of 1.0 mm in diameter 
and scored for immunohistochemical staining intensity as previously described (24). The 
majority of samples were successfully prepared (~95%) and Gleason grades were evaluated by a 
national board-certified pathologist (L. Helczynski) in the prostate cancer specimens from 351 
before preparation of TMA. The group of samples consisted of 246 samples with Gleason grade 
3 and 105 samples with Gleason grade 4-5. The study was approved by the Ethics committee, 
Lund University and the Helsinki Declaration of Human Rights was strictly observed. 
Immunohistochemistry  
Immunohistochemical staining of paraffin embedded sections from human TMA blocks was 
performed as previously described(25). Mouse antibody against HO-1 (Stressgen, #OSA-110) 
was used at 1:200 dilution. Secondary antibody was used as a negative control. 
Immunohistochemistry, immunofluorescence and immunostaining on the cell lines and mouse 
tumor samples were performed as previously described37. Briefly, formalin-fixed or Zn-fixed 
paraffin embedded tumor tissues were processed for antigen retrieval with high pressure-
cooking in citrate buffer for 1 hour. Tissues sections were then blocked with 7% horse serum for 
30 min, followed by incubation with primary antibody overnight. Biotin-labeled secondary 
antibody (Vector Laboratories) was applied for 1h at RT followed by Vectastain Elite ABC Kit 
and detection with ImmPact DAB (Vector Laboratories).  Immunofluorescence staining was 
performed on frozen tumor sections or cultured cells on glass cover slips. Tissues or cells were 
fixed with 2% paraformaldehyde for 10 min followed by permeabilization with 0.05% Triton X-
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100. After blocking with 7% horse serum, sections were probed with primary antibody and 
secondary fluorescently labeled antibody (Molecular Probes). Hoechst-33258 (Molecular 
Probes, Invitrogen) was used to stain the nuclei. 
The following antibodies were applied: polyclonal rabbit anti-HO-1 (Stressgen) was 
used at 1:1000. Prohibitin antibody was purchased from Epitomics Inc. (Burlingame, CA). 
Cytochrome C antibody was obtained from Cell Signaling (Beverly, MA). mtTFA and vimentin 
antibodies were purchased from Santa Cruz Biotechnology. Anti-mouse Ki67 antibody was 
from Dako. Anti-mouse Thy-1, CD31, antibody was from BD Biosciences, Pharmingen and 
anti-P (Ser10)-Histone H3 were from Cell Signaling. TUNEL staining was performed using 
ApopTag Peroxidase in situ apoptosis detection Kit (Chemicon, Millipore, Billerica, MA) 
following manufacturer’s protocol. 
 
Animal tumor models  
The tumor models were approved by the BIDMC IACUC. Nu/nu mice were purchased from 
Taconic (Hudson, NY) at 7 weeks of age. Mice were provided food and water ad libitum as 
needed. After 1-week acclimatization, 1x106 PC3 cells were injected into the right flank of 
mice. Tumors were established for 2 weeks at which point treatment with CO±doxorubicin was 
begun. Mice were exposed to CO (250ppm, 1 hr/day) as previously described (26). Doxorubicin 
(8 mg/kg) was given i.v. twice per week just prior to CO/Air exposure. Tumor volume (0.52 x 
width x length) was measured and calculated every day for 14 days. After 14 days, mice were 
sacrificed and tumors were harvested.  In the orthotopic model of PC3 xenografts, 1x106 PC3 
cells were injected to the right lobe of prostate under anesthesia. Tumors (n=4 per group) were 
established for 2 weeks followed by CO /Air treatment for 4 weeks. CO was administrated 
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every day for 1h at 250ppm. TRAMP mice  (Jackson Laboratories) were treated with CO (250 
ppm/day, 5 days/week) starting at 5 weeks of age. Treatment was continued for 20 weeks. 
Tumors were harvested and process for immunohistochemical analysis thereafter. Kras4bG12D 
transgenic mice were kindly provided by Dr. Varmus and were on doxycycline chow at 5 weeks 
of age and CO was started after 8 weeks of doxycyline treatment. CO (250 ppm, 5 days/week) 
was continued for 5 weeks and the lung were harvested for histology. 
Cell culture and treatment 
The human prostatic cell line, PC3, human breast cancer cells (MDA-468 and T47D), 
hepatocarcinoma (HepG2), cervical cancer cells (HeLA), skin fibroblasts  (NIH3T3) and lung 
adenocarcinoma cell line (A549) were purchased from American Type Culture Collection 
(ATCC, Manassas VA) or provided by Dr. Balk and Dr. Chen (BIDMC) and were cultured in 
RPMI or DMEM medium supplemented with 10% FBS and antibiotics. Human bronchial 
epithelial cells were purchased from AATC and cultured following manufacturer’s protocol. 
PNT1A were kindly gifted by Dr. Nishtman Dizeyi (Lund University, Malmo, Sweden) and 
were cultured in RPMI medium supplemented with 10% FBS and antibiotics. A549 rho(o) cells 
that are deprived of mitochondria were generated after 3 weeks of culture in medium containing 
ethidium bromide (20 μg/ml). Mouse embryonic fibroblasts from p53+/+ and p53-/-  mice were 
kindly gifted by Dr. Tyler Jacks (MIT, Boston) and were cultured in DMEM medium with 10% 
FBS and antibiotics. Cells were treated with camptothecin (0.001μg/ml-10 μg /ml, Sigma) or 
doxorubicin (10 μg/ml, Sigma) and vehicle control (DMSO) for 1-24 hours. Co-treatment with 
CO (250 ppm) was performed as previously described (26). Pegylated catalase (3000 U/ml) and 
SOD (10 U/ml) were from Sigma and were used 1h prior to CO treatment.  
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Transient transfection 
PC3 cells were transfected using Amaxa nucleofection or Lipofectamine 2000 as 
previously described (24). pCMV control vector or human HO-1 cDNA encoding vector were 
used for transfection. Transfection efficiency was between 40-50% as estimated with 
overexpression of GFP by fluorescence microscopy. 
Comet assay 
PC3 cells were treated with CO or Air for 24h and harvested for COMET SCGE Assay 
(Assay Designs). The manufacturer’s protocol was followed. Cells were viewed by Zeiss 
Axiovert Apotome Fluorescent microscope at 40x. At least 100 cells were counted and the 
amount of comets was calculated and expressed per 100 cells.  
Immunoblotting  
         Cells were lysed by brief sonication in ice-cold lysis buffer (150mM NaCl, 50mM Tris-
HCl pH 7.5, 1% NP-40, 10 mM NaF, 1% SDS, 1 mM EDTA pH 8.0, 10 mM 
phenylmethylsulfonyl fluoride (PMSF) and the protease inhibitor cocktail Complete Mini 
(Roche). Samples were centrifuged for 20 min 14000xg at 4 °C and clear supernatants were 
collected. Protein concentrations were measured using a BCA Protein Assay Kit (Pierce, 
Rockford, IL). 20-30 μg of each protein sample were electrophoresed on a NuPAGE 4-12% Bis-
Tris Gel (Invitrogen) in NuPAGE MES SDS Running Buffer (Invitrogen) followed by transfer 
to PVDF membrane (Ready Gel Blotting Sandwiches; BioRad). The membranes were blocked 
with 5% non-fat dry milk, probed with appropriate primary antibodies at concentration of 
1:1000 followed by horseradish peroxidase (HRP)-conjugated secondary antibodies at a dilution 
of 1:5000 and visualized using Super Signal West Pico chemiluminescent substrate (Pierce) or 
Femto Maximum Sensitivity substrate (Pierce), followed by exposure to the autoradiography 
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film (ISC BioExpress). The following antibodies were applied: rabbit anti-Caspase-3, rabbit 
anti-cleaved caspase-3 (Cell Signaling Technologies), goat anti-Gadd45 (Santa Cruz 
Biotechnology), rabbit anti-heme oxygenase-1 (RDI-Fitzgerald Industries Int), mouse anti-β-
actin (Sigma-Aldrich), mouse anti-GAPDH (Calbiochem), rabbit anti-cyclin A2 (Santa Cruz 
Biotechnology).  
HO-1 activity and CO levels in the tissues 
PC3 cells were treated with 10 μg/ml doxorubicin or camptothecin for 4 hours and 
nuclear/cytoplasmic fractions were isolated. HO-1 activity was measured as previously 
described (27). We assume that only HO-1 was contributing to the changes in HO activity assay 
as HO-2 remained unchanged in response to doxorubicin and camptothecin treatment for 4 
hours (data not shown). Measurements of CO concentrations were performed on tissue sections 
as described by Verma et al.(28). Tumor and normal tissues were harvested immediately after 
the last exposure of mice to CO and tissues were processed for gas chromatography as 
described. Briefly, CO was liberated as a gas in a sealed glass vial by adding 25l of water and 
5 l of sulfosalicylic acid (SSA; 30% [wt/vol]) to 30 l of diluted tissue homogenate. The vials 
were incubated on ice for 10 min before being analyzed. The gas in the headspace of the vials 
was then analyzed quantitatively with a gas chromatograph (GC) equipped with a reducing-
compound photometry (RCP) detector (Peak Laboratories, Mountain View, CA), which allowed 
the CO in gas to be quantified to concentrations as low as 1 to 2 parts per billion (ppb). The 
amount of CO was then calculated using a calibration curve prepared from CO standards. 
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RNA isolation and real time PCR 
Total RNA was isolated from PC3 cells after treatment with 10 μg/ml camptothecin with 
or without CO for 6 or 24 hours using RNeasy Kit (Qiagen, Inc). 2 μg of RNA was used for 
cDNA synthesis (Invitrogen, Carlsbad, CA). The region of Gadd45α was amplified with 
specific primers: F-5’ TGCTCAGCAAAGCCCTGAGT3’; R-
5’GCAGGCACAACACCACGTTA3’. The following primers to β-actin were used: F- 
5’CGCGAGAGAAGATGACCCAGATC3’; R-5’TCACCGGAGTCCATCACGA3’. Real time 
PCR reactions were performed using 1xSYBR Green PCR Master Mix (BioRad). Primers for 
MMP2, urokinase plasminogen activator (uPA), VEGF were previously described (24). 
Apoptosis, viability and clonogenic assays 
PC3 cells were seeded at 1x105 concentration in 6 well plates 24 hours before 
experiment. Cells were treated with camptothecin (0.001-10 μg/ml) or doxorubicin (10 μg/ml) 
with CO/Air for 24 hours. Cells were harvested and apoptosis rate was measured using Annexin 
V-FITC staining according to the manufacturer’s protocol (BD Biosciences, San Jose, CA). To 
test cell viability, PC3 cells were stained with Crystal Violet solution (Sigma-Aldrich) for 10 
minutes, followed by extensive wash with double-distilled water. Cells were dried and dissolved 
in 10% acetic acid, followed by measurement of absorbance at 560 nm on the ELISA reader. 
Clonogenic assay: cells were treated in the presence or absence of CO ± chemotherapeutics as 
above for 24h. After 24h cells were trypsinized and seeded as a subculture with dilution of 1:10-
1:100. Colony counts were performed 2 weeks after seeding.  
Cell Fractionation 
Nuclear and cytoplasmic fraction of PC3 cells were performed using the subcellular 
fractionation Kit following the manufacturer’s protocol (Pierce, Rockford, IL) or BioVision 
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Nuclear/Cytoplasmic Kit extraction (BioVision). Briefly, cells were treated as described above, 
washed twice with PBS and trypsinized. Pellets were collected and resuspended in ice-cold 
Cytoplasmic Extraction Reagent (CERI) buffer and vortexed. Lysates were incubated on ice for 
10 min and Cytoplasmic Extraction Reagent II (CERII) buffer was added and lysates were 
incubated for additional 1min on ice. After vortexing, lysates were centrifuge at 16,000 x g and 
supernatants were collected for the cytoplasmic fraction. Pellets were resuspended in ice-cold 
Nuclear Extraction Reagent (NER) buffer and incubated on ice for 30 min. Nuclear and 
cytoplasmic fractions were analyzed by immunoblotting as described above. 
Mitochondrial activity and metabolic profiling 
SPECT: We used technetium-99m methoxyisobutyl isonitrile (99mTc-sestamibi) single 
photon emission computed tomography (SPECT) in PC3 cells treated with CO (250 ppm) or 
CORM-A1 (20 or 100 μM) for 24 h in vitro. Technetium labeling was performed at BIDM 
Imaging Facility and the radiation intensity was evaluated that corresponded to the 
mitochondrial activity.   
Seahorse Experiments 
  Cells were seeded in 24 well plate (3x104) 24 h prior experiment and treated with CO 
(250 ppm) or Air for 30 minutes or CO was bubbled into the medium and transferred to the 
reader immediately prior measurment. Oxygen consumption rate (OCR) and extracellular 
acidification rate (ECAR) were measured over time.  
LDH and glucose measurments 
PC3 cells were  treated for 6 hours with CO (250 ppm) and harvested in the 
manufacturer’s lysis buffers to measure glucose or lactate (Biovision, Glucose or Lactate Kits) 
and process for colorimetric analysis of metabolites.  
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MitoTracker Red 
  CMCRos was purchased from Invitrogen, Molecular Probes and was used at 0.2 μM 
concentration. Cells were treated for 3.5 hours with Doxorubicin (10 ng/ml) ± CO and 
MitroTracker Red CMCRos was added for the last 30 min of treatment. Cells were washed and 
fixed with 2% PFA followed by staining with Hoechst.  
Statistical analyses 
Statistical analyses were performed using SPSS version 13.0 (SPSS Inc., Chicago, IL). 
The differences in the expression of different markers between benign and cancer specimens 
were evaluated by paired Wilcoxon’s rank sum test or Kruskal-Wallis test. Distributions of 
overall survival and disease-free survival were estimated by the method of Kaplan-Meier, with 
95% confidence intervals. Differences between survival curves were calculated using the log-
rank test. Data are presented as the mean ±SD and are representative for at least three 
independent experiments. Student T, ANOVA, Wilcoxon tests were used for estimation of 
statistical significance for the experiments (p<0.05). 
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Results 
Nuclear HO-1 with low activity in prostate cancer correlates with poorer prognosis. 
HO-1 has been shown to be expressed and function in the nucleus as a regulator of 
oxidative stress response transcription factor at the expense, however, of losing enzymatic 
activity(29). Based on these data, we hypothesized that nuclear translocation of HO-1 influences 
the response of cancer cells to therapy. We evaluated 482 tumor specimens from patients with 
prostate cancer with corresponding benign tissues by tissue microarray to assess the correlation 
between nuclear HO-1 expression and clinical tumor characteristics. The majority of benign 
samples showed low overall expression of HO-1 (Fig 1A-B and Supplementary Fig1A). In 
contrast, Gleason grade 3 specimens showed significantly higher expression of HO-1 in the 
nucleus than that of corresponding benign tissue (Fig 1C-D, p=0.047*). The intensity of nuclear 
HO-1 staining declined in Gleason grade 4-5 specimens as compare to Gleason grade 3, but did 
not achieve statistical significance (Fig 1A-H). Finally, there was no significant difference in 
cytoplasmic staining of HO-1 in prostate cancer versus adjacent benign samples (data not 
shown). We reasoned that high nuclear HO-1 expression in moderately differentiated tumors 
may correspond to the level of oxidative stress or hypoxia that drives progression of 
differentiated tumors to more advanced disease. 
We next evaluated the clinical significance of nuclear HO-1 expression by correlating 
HO-1 staining with biochemical recurrence (BCR) of PCa as measured by prostate-specific 
antigen in the circulation(30) as well as overall patient survival (Fig 1H). High nuclear HO-1 
(arbitrary intensity= 3) expression in the cancer biopsies in comparison to low (arbitrary 
intensity =1) nuclear HO-1 predicts a shorter time to BCR (Fig 1F, p=0.007*). After a 20-30 
month follow-up period, a 20% greater number of patients with high nuclear HO-1 relapsed in 
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comparison to patients with low nuclear HO-1 (p=0.046) indicating a shorter time to recurrent 
disease in PCa patients with a lack of enzymatically active nuclear HO-1.  
 
HO-1 Activity and CO Influence the Cancer Cell Response to Genotoxins 
Nuclear localized HO-1 is a hallmark of cancer progression in PCa(18). Comparing the 
HO-1 localization profiles and activity of non-cancerous cells (epithelial cells and fibroblasts) to 
cancerous cells (PC3, A549, HepG2, T47D, MDA-468, HeLa) we found that cancer cell lines 
showed high nuclear expression and low cytoplasmic expression while non-cancerous cells 
showed high cytosolic expression and low nuclear expression (Fig 2A-B).  We show that when 
HO-1 is localized to the nucleus it loses its activity in response to common chemotherapeutics 
(Fig 2C and Lin, 2007).  Based on nuclear localization of HO-1 with low activity(29), we next 
asked whether HO-1 is important in mediating the effectiveness of chemotherapeutic treatment 
in vitro. DNA damage causes mutations and carcinogenesis as well as induces cancer cell death. 
HO-1 expression in normal cells is required for appropriate DNA repair in response to 
chemotherapy or irradiation(31). Using camptothecin and doxorubicin to induce DNA damage, 
we tested the role of HO-1 and CO on cancer and normal cell death. We observed significant 
cell death with camptothecin or doxorubicin in vector control-treated PC3 cells as expected. 
Overexpression of HO-1 induced further death of PC3 cells in response to camptothecin or 
doxorubicin (Fig 2D). A similar effect was observed in cells after exposure to a low 
concentration of CO (Fig 2 and Supplementary Fig 1B-C).(32) Dose escalation experiments to 
induce cell death with camptothecin showed that in the presence of CO, the sensitivity of cells 
to camptothecin increased synergistically to approximately 1000 fold over chemotherapy-alone-
treated cells (Fig 2E and Supplementary Figure 1B-C).  The effect was specific to DNA 
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damage inducing agents as apoptotic responses induced by TNF and cyclohexamide were not 
altered after CO treatment (data not shown). Further evidence of the effects of CO on PC3 cells 
in the presence of camptothecin showed that compared to air controls, CO induced significantly 
stronger cleavage of caspase 3, augmented DNA damage as measured by comet assay, and 
induced Gadd45α expression, an important regulator of apoptosis and DNA repair that is 
induced in response to chemotherapy (Supplementary Fig 1 D-F and Supplementary Fig 2).  
Many reports detail the protective effects afforded by CO and HO-1 in response to 
oxidative stress in primary cells (33-35), which is in contrast to the above effects in prostate 
cancer cells. Treatment of normal prostate epithelial cells (PNT1A) with doxorubicin showed 
that unlike prostate cancer cells, CO prevented doxorubicin-induced death of normal prostate 
cells (Fig 2F and Supplementary Fig 1G) supporting the remarkable selectivity of HO-1 and 
CO to enhance killing of tumor cells while protecting primary cells. We confirmed these 
findings using primary mouse embryonic fibroblasts (MEF) treated with camptothecin or 
doxorubicin at the highest doses used in cancer cells and evaluated the effects of CO. As 
expected we observed 75-90% cell death in response to both chemotherapeutics in air-treated 
cells. Similar to PNT1A, CO protected primary mouse embryonic fibroblasts (MEF) against 
doxorubicin-induced cell death versus air-treated cells (Supplementary Fig 1H). The protection 
of primary cells afforded by CO is independent of p53, a well-characterized modulator of cell 
death in response to DNA damage. CO was also able to protect p53-/- MEF (Supplementary 
Fig 1H).  
 
Carbon monoxide inhibits growth of human prostate cancer xenografts. 
 16
We next evaluated the role of CO alone and CO in combination with doxorubicin on the 
growth of tumors in vivo, employing PC3 human prostate cancer xenografts implanted 
subcutaneously in nude mice. Mice with established tumors were exposed to a regimen of CO 
(250 ppm for one hr once/day at the same time of day) ± doxorubicin (doxorubicin was injected 
immediately after CO treatment) and growth was monitored over 2 weeks at which point 
volumes of tumors were measured and harvested for histological analyses. Mice treated with 
CO or doxorubicin alone showed significant tumor growth arrest versus controls as measured by 
tumor volume and Ki67 expression and had no effect on body weight (Fig 3A and 
Supplementary Fig 3A-B). Combination treatment with doxorubicin plus CO showed further 
additive effects with regard to tumor size, proliferative index and neovascularization (Fig 3B-
F). We did, however, observe a significant effect of CO alone or in combination with 
doxorubicin on cell death that was not observed with doxorubicin alone suggesting a distinct 
cellular target for CO (Fig 3G-H).  Mitotic catastrophe as assessed by occurrence of aberrant 
nuclei after cell division was present among the P-Histone H3 positive cells in tumors treated 
with CO or doxorubicin (insets in Fig 3E).  Validation of the effects of CO with 
immunostaining showed that CO inhibited the cell cycle marker cyclin A2 (densitometric 
analyses: Air+Dox: 1.15±0.28, CO+Dox: 0.68±0.09, p<0.05; Supplementary Fig 4A-B). The 
number of Thy positive fibroblasts was markedly decreased in animals receiving CO versus Air 
treatment. It was not determined whether this was due to less infiltration or increased cell death 
(Supplementary Fig 4C). Depletion of Thy-1 positive stromal cells may be an additional early 
molecular target of CO leading to accelerated cell death and inhibition of angiogenesis. The 
contribution of endothelial cell proliferation and recruitment of stroma cells in addition to tumor 
cell growth needs to be further evaluated.   
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Carbon monoxide induces apoptosis and blocks mitosis and angiogenesis in a model of 
orthotopic prostate cancer in mice. 
In a more clinically relevant model of orthotopic PC3 prostate cancer tumors, CO 
suppressed the mitotic index as measured by P-Histone H3 and CD31 staining in established 
tumors (8% and 6% respectively, Fig 4A-C). Importantly, CO significantly suppressed a key 
marker of invasion and early metastasis known as urokinase type plasminogen activator (uPA) 
(Fig 4D). Further, CO showed the trend towards decreased expression of the tumor markers 
MMP2 and VEGF, however it did not reach significance (Fig 4D).  Similar to the subcutaneous 
tumor xenograft model, CO induced greater cell death in orthotopic tumors as compared to 
tumors from air-treated mice (Fig 4E-F; 35% in CO versus 15% in Air) suggesting that in 
addition to arresting growth, CO reduced the invasive and aggressive phenotype with a 
signature of mitochondrial collapse and tissue necrosis. This was different then that observed in 
vitro where CO alone did not affect cancer cell death yet inhibited cell cycle. In both tumor 
models, we observed a significant increase in the amount of CO present within the tumor tissue 
as well as in the liver and lung of CO-exposed mice (Fig 4G and data not shown). 
 
Carbon monoxide prevents development of PIN/carcinoma lesions in TRAMP mice and 
inhibits lung carcinoma growth in Kras4bG12D transgenic mice  
CO was tested in two additional models of spontaneously developed tumors using the 
prostate tumor TRAMP and the lung tumor Kras mouse models(36, 37). We started CO 
treatment in mice 8-20 weeks of age, which is after tumors are established(36, 37).  Untreated 
mice showed a high proliferative index as measured by Ki-67 staining in the tumors showing 
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multiple PIN foci and adenocarcinoma (Fig 5A-B). In contrast, CO-treated mice had fewer PIN 
foci and significantly less Ki-67 positive cells and some of the CO-treated TRAMP mice were 
completely lesion-free (Fig 5A-B). Importantly, during the progression of the disease and in 
contrast to the normal prostate where HO-1 is localized to the cytoplasm, HO-1 was expressed 
in the nucleus in the PIN lesions (Fig 5C). Staining for the mitochondrial stress response marker 
mtTFA showed a significant increase in the number of mitochondria in the lesions of CO-
treated TRAMP mice as compared to the neoplastic lesions in Air-treated TRAMP mice at the 
same age (Fig 5D). 
A similar effect on tumor growth was observed in the Kras lung tumor model where we 
observed a significant inhibition in both the frequency (average, n=24 in Air vs n=15 in CO) as 
well as the size of the tumor nodules in the lung in animals treated with CO versus Air (Fig 5E). 
Proliferation of tumors was also significantly inhibited as evidenced by decreased Ki67 staining 
(Figure 5F). Longer treatment with CO resulted in further inhibition of tumor growth and size 
of the nodules (data not shown).  
 
Carbon monoxide targets mitochondria to induce death of cancer cells  
We next explored potential molecular mechanisms by which CO exerted its effects using 
prostate cancer cells as our model.  Of note, HO-1 and CO have been shown to induce growth 
arrest of human cancer cells(38) as well as murine AC29 mesothelioma cells (55% less cells at 
day 2 and 80% at day 5 vs air controls) which support a more global effect of CO in different 
type of cancer cells. Given that CO is known to target mitochondria, and the data presented in 
Fig 3, we next assessed the activity and number of mitochondria in cancer cells in the presence 
and absence of CO. CO increased oxygen consumption rate (OCR) within minutes after 
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exposure which was accompanied by reactive oxygen species (ROS) generation in PC3 cells 
that correlated with decreased extracellular acidification rates (ECAR) and lactate levels (Fig 
6A-E). Use of the mitochondrial complex I poison rotenone to compare CO to another 
mitochondrial targeting compound and whether it would have similar effects in these cells as 
CO, showed complete blockage of the OCR as was expected with rotenone and this effect 
occurred in both cancer and non-cancer cells (Fig 6B). We also tested mitochondrial potential 
using the JC-1 dye. As previously reported in other cell types(39) CO increased mitochondria 
membrane potential in PC3 cells (Supplementary Fig 5). CO did inhibit OCR in normal cells, 
again suggesting a selective difference in the response of cancer cells and normal PNT1A cells 
to CO (Fig 6B). The activation of mitochondrial activity by CO is likely contributes to a less 
cancerous phenotype.  As the treatment time with CO was extended, PC3 cells showed clear G1 
arrest (Fig 6F), which corresponded to significant inhibition of metabolic activity of cancer cells 
as measured by SPECT (Fig 6G). Further, exposure to CO induced mitochondrial stress as 
evidenced by increased mtTFA, cytochrome C positive staining and an inhibition in the 
oxidized state of mitochondria (Fig 6H-K).  Metabolic screening showed that exposure of PC3 
cells to CO for 6h resulted in a decrease in glucose metabolism and influenced synthetic 
pathways involved in nucleotide and amino acid synthesis all of which corroborate the effects of 
CO on cancer cell growth (Table 1, Supplementary Table S1 and Supplementary Fig 6).   
In efforts to further investigate the role of mitochondria in the effects observed with CO, 
we depleted mitochondria from cancer cells (Rhoo cells), which resulted in epithelial to 
mesenchymal transition as evident by the emergence of fibroblast-like shaped cells and 
enhanced expression of vimentin in the Rhoo cells compared to control which was unaffected by 
CO further suggestive of mitochondrial targeting by CO (Fig 6L). Rhoo cells are more prone to 
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doxorubicin-induced cell death then normal cells however CO did not amplify the effects of 
doxorubicin in these cells in contrast to normal cells (% of surviving colonies: A549- 
Air+Doxorubiicn: 29.8±1.2 %, CO+Doxorubicin: 13.4±0.7%, A549Rhoo. Air+Doxorubicin: 
17.1±1%, CO+Doxorubicin: 17.6±0.39%). Based on changes in mitochondrial function 
described above and the specifically the increase in ROS generation, we next depleted ROS 
using a cocktail of pegylated catalase and superoxide dismutase. Addition of the antioxidant 
cocktail prior to treatment with CO resulted in reversal of the effects of CO on doxorubicin-
induced apoptosis further supporting ROS and the mitochondria as the cellular target for CO 
(Supplementary Figure 7). 
 
Discussion 
 In the present study, we elucidate a role for carbon monoxide in modulation of prostate 
and lung tumor growth and survival. CO not only mimics the effects of chemotherapy alone by 
blocking proliferation, but also amplifies tumor cell death when treated in combination with 
either doxorubicin or camptothecin. Further, we provide evidence that CO reduces the tumor 
burden in xenograft and transgenic mouse models of prostate and lung cancers and effectively 
blocks progression of neoplasia and adenocarcinoma. We deduce that CO effectively switches 
the metabolic state of the cancer cell to fuel oxidative metabolism and decreases in nucleotide 
and amino acid synthetic pathways. Collectively this causes cell cycle arrest and collapse under 
intense mitochondrial-dependent oxidative stress. In vitro, this elicits a 1000 fold increase in 
sensitivity to genotoxins fostered in part by a mitochondria-dependent increase in reactive 
oxygen species (ROS) generation. In vivo, the role of CO and ROS on tumor growth is less clear 
and likely involves other cellular mechanisms including hypoxia and perhaps a heightened 
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immune response. Importantly, CO protects normal cells from DNA damage by cytotoxic 
agents in part by reducing oxygen consumption and eliciting a hibernation-like state that has 
been observed in other cell types such as T cells and smooth muscle cells with the induction of 
DNA repair complexes(40). 
  HO-1 is an accepted cytoprotective gene in most stress-related pathologies acting to 
reestablish homeostasis(41, 42).  Others and we have shown that nuclear localized HO-1 no 
longer possesses enzymatic activity and as such becomes highly associated with cancer and 
tumor growth(29, 43).  We demonstrate that CO can mimic the effects of enzymatically active 
HO-1 and that exposure to CO or reinstating HO-1 activity results in enhanced sensitization and 
acceleration of apoptosis of cancer cells and tumors while protecting normal cells against 
chemotherapeutic toxicity. This is consistent with prior observations that HO-1-derived CO is 
important in DNA repair in normal cells(31). We posit that the subsequent decrease in 
endogenous CO generation when HO-1 is in the nucleus results in accelerated DNA stress and 
damage and thus serves as a hallmark of early carcinogenesis.   
In our cohort of patients, nuclear HO-1 is increased in a subset of PCa patients with a 
shorter time to BCR. We did not observe a significant association of HO-1 expression with 
Gleason grades due to the relatively low number of cohort cases with the most advanced disease 
(Gleason grade 5). We would anticipate however statistically significant correlations in a larger 
cohort of patients as reported by Sacca et al. who showed a clear association between HO-1 and 
prostate cancer incidence.  Inhibition of HO-1 pharmacologically using zinc-protoporphyrin 
(Zn-PP) induced apoptosis and suppressed growth of sarcomas in rats(44), but Zn-PP treatment 
failed to potentiate the anti-tumor effects of 5-fluorouracil, cisplatin and doxorubicin in three 
different tumor models(45). HO-1 overexpression or CO exposure reduced TPA-induced 
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invasion of breast cancer cells(13) as well as lung adenocarcinoma cells(38). The effects of HO-
1 on tumor growth and progression is complex and likely depends on cancer types, the cell cycle 
status, the model system, as well as the methods of pharmacologic or genetic manipulation of 
HO-1 activity. 
In our model of human tumor xenografts in vivo, we observed strong inhibition of 
angiogenic markers, mitosis and accelerated apoptosis in tumors treated with CO. Further, CO 
sensitized cancer cells and solid tumors to apoptosis with apparent mitotic catastrophe likely 
influenced by cellular exhaustion as evidenced by our biochemical data (Figure 6). The effects 
of CO on mitochondria have been well described and we speculate that the high metabolic 
requirements of cancer cells lends itself to greater effects of CO on survival given that CO is 
known to target mitochondrial respiratory complexes(32). This is supported by the effects of CO 
on mitochondrial membrane potential(46), biogenesis(35), and decreased prohibitin (data not 
shown), which regulate cancer cell survival and growth.  PC-3 xenografts are partially resistant 
to doxorubicin induced apoptosis which delays tumor growth through mitotic blockade(47). 
This effect was amplified by the presence of CO in vitro and in vivo.   The increase in ROS by 
CO in cancer cells, likely augments protein and mitochondrial DNA.(48). Indeed, inhibition of 
HO-1 activity in prostate cancer cells correlated with a reduction in protein carbonylation and 
reactive oxygen species formation(49).  
The finding that CO protects normal cells from genotoxin toxicity offers an added 
benefit and may permit chemosparing therapy thus decreasing negative side effects. We have 
not tested the response to irradiation, however considering that CO protects normal cells against 
cell death via amplification of DNA repair(31), we expect that CO may have similar sparing 
effects on normal cells in response to irradiation while amplifying cancer cell death in response 
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to irradiation.  CO-elicited protection of normal cells suggests that normal cells tolerate 
alterations in metabolic demands more efficiently and are more capable of repairing damaged 
DNA. The effect of CO to enhance killing is not specific to prostate cancer cells, as we observed 
accelerated cell death of breast, lung and other prostate cancer cell lines treated with 
doxorubicin and CO as well as dysregulated smooth muscle cells that lead to vascular stenosis 
in models of angioplasty, transplantation and pulmonary hypertension.  CO at these doses has 
no untoward effects on the animals and in fact also protects against doxorubicin induced 
cardiomyopathy(35).   
 In summary, we demonstrate that HO-1 expression in cancer specimens is targeted to the 
nucleus in moderately differentiated tumor cells for reasons that remain to be elucidated.  
Collectively, CO influences cellular bioenergetics that we find differs between cancer cells and 
normal cells. CO accelerates oxidative metabolism and ROS generation, unlike in non-cancer 
cells where CO inhibits respiration and protects against cell death.  Insufficient respiration due 
to dysfunctional mitochondria drives what is known as the Warburg effect.  Exposure to CO 
employs Warburg physiology as an advantage; compelling the cancer cell to consume more 
oxygen that in turn drives metabolic demand leading to growth inhibition, cellular exhaustion 
and death. These data provide the first evidence demonstrating the potential for safe, low 
amounts of CO to be used as an adjuvant therapeutic option for the treatment of cancer. One 
might envision a specific inhalational therapy regimen being implemented such as that used here 
to treat cancer patients with inhaled CO using a specific metered dosing delivery device or a CO 
releasing molecule (CO-RM) (50). 
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Table 1 
Metabolic analysis was performed using MetaboAnalyst 2.0. Top 13 metabolites out of 290 
metabolites were inhibited by CO (250ppm, 6h) treatment of PC3 cells by more then 5-fold. 
N=3 in duplicates. Univariate 	
analysis was performed by MetaboAnalyst 2.0 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Peaks(mz/rt) Fold Change 
S-adenosyl-L-homoCysteine-
positive 
7.9552 
S-adenosyl-L-homocysteine-
negative 
7.8218 
1-Methyladenosine 6.7669 
NADH-nega 6.2849 
2-deoxyglucose-6-phosphate 6.0176 
Pyridoxine 5.4215 
Pyridoxamine 5.4073 
NG-dimethyl-L-arginine 5.3147 
Pyrophosphate 5.1344 
Ribose-phosphate 5.0937 
NADH 5.0912 
Thymine 5.0494 
3-phospho-serine 5.0256 
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Figure Legends 
Figure 1. Nuclear expression of HO-1 in 482 biopsy samples of human PCa. A-B. 
Representative pictures of HO-1 staining in specimens from benign tissues adjacent to prostate 
cancer cells of Gleason grade 3 (C-D) and Gleason grade 4-5 (E-F). 40x magnification (insets at 
100x). G. Statistical analysis of nuclear HO-1 expression in different stages of PCa (Gleason 3 
and 4-5) vs adjacent benign tissues (BPH). *p<0.05 PCa versus BPH. H. Survival curves of time 
to relapse against low or high nuclear HO-1 expression in samples from all biopsies. Low 
nuclear staining intensity corresponds to a score of 1 and high nuclear staining intensity 
corresponds to a score of 3. *p=0.046. Images are representative of all biopsies. Scale bar, 50 
μm. 
 
Figure 2. Nuclear HO-1 is enzymatically inactive. A-B. Immunoblot of HO-1 in the nuclear 
(A) and cytoplasmic (B) fractions of various normal (NIH3T3 fibroblasts- NIH, primary human 
bronchial epithelial cells-E, primary lung fibroblasts-F) as well as cancer cells lines (PC3-PC, 
A549-A5, HepG2-Hep, HeLa-Hel, T47D-T47, MDA-468-MD). Data are representative of 3 
independent experiments. C. HO-1 activity in the nuclear (white bars) and cytoplasmic (black 
bars) fractions of PC3 cells treated with camptothecin (1 μg/ml) or doxorubicin (10 μg/ml) for 4 
hours *p<0.05. D. Crystal violet staining of PC3 cells overexpressing HO-1 (black bars) or 
control vector (white bars) treated for 24h with camptothecin (1-10 μg/ml) or doxorubicin (1-10 
μg/ml). #p<0.05 doxorubicin/camptothecin treated versus untreated; ** p<0.01 HO-1 versus 
Control vector. E. Dose-dependent treatment of PC3 cells with camptothecin (0.001-10 μg/ml) 
± CO for 24h.  **p<0.01, *p<0.05 CO±camptothecin (black bars) vs Air±camptothecin (white 
bars). F. Cell viability was measured by crystal violet staining of PNT1A normal primary 
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prostate epithelial cells treated with doxorubicin (10 mg/ml) ± CO (black bars) or Air (white 
bars) for 48 hours. *CO+Doxorubicin vs Air+Doxorubicin, p<0.05.  
 
Figure 3. CO blocks tumor growth of established PC3 xenografts and sensitizes tumor 
cells to doxorubicin treatment  A-B. Growth curves (% of original tumor volume) of PC3 cells 
inoculated into nude mice for 2 weeks prior to initiation of treatment with air or CO (250 ppm, 
1h day) ± Doxorubicin, which was continued for an additional two weeks before harvest. 
Results are mean ± SD of n=4-5 per group. C-F. Immunostaining of CD31 (C) and P-Histone 
H3 (E) in PC3 tumors. Quantitation of CD31 (D) or PH3-positive (F) cells was counted as the 
percentage of positive cells/field of view (20x magnification). Results represent mean±SD of 8-
10 sections from each harvested tumor.  E-F. TUNEL staining quantitated as % of positive cells 
per field of view (20x magnification). Results represent mean±SD of 8-10 sections from each 
harvested tumor.  **p<0.01vs Air; *p<0.05 vs Air.  
 
Figure 4. CO induces apoptosis in an orthotopic prostate cancer model in mice.  A-C. Co-
immunostaining of P-Histone H3 (green) and CD31 (red) of orthotopic tumors in mice treated 
for 4 weeks with CO or Air. Representative pictures are shown in A, and quantification of 
staining is shown in B-C (n=4 per group). Scale bar, 50 μm. D. Real time PCR with primers for 
MMP2, VEGF and urokinase plasminogen activator (uPA) in mice treated with CO or Air. 
Results represent mean±SD of n=4 tumors/group. * p<0.05 vs control. E-F. TUNEL staining for 
apoptosis and the % of positive cells per field of view (20x magnification) quantitated as above.  
Images are representative of 8-10 sections from each harvested tumor. Results represent mean ± 
SD of 8-10 fields of view from each tumor. **p<0.01 vs air. G. CO levels in the tumors from 
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mice with subcutaneously or orthotopically inoculated tumors. n=3-6 per group. Scale bar, 100 
μm. 
 
 
 
Figure 5. CO arrests growth of established prostate and lung cancer A-B. 
Immunohistochemistry analysis with antibody against Ki67 and histological analysis (H&E) 
was performed on the tissues from wild type (wt) or TRAMP mice that were treated with CO 
(250 ppm/daily/5 days per week) or untreated (Air). Quantitation of Ki67 staining is shown in A 
(n=6-7 mice per group). C. Immunohistochemistry with antibodies to HO-1 was applied in the 
normal (wt) and PIN lesion containing prostates (TRAMP) as well as in the lung tumors of 
FVB/N-Tg(teto-Kras2)12Hev (provided by Dr. Varmus). Scale bar, 200 μm. D. 
Immunostaining of prostates from TRAMP treated as above with antibodies to mitochondrial 
transcription factor A. Two representative pictures from Air and CO treated mice are shown. 
Scale bar, 200 μm. E-F. H&E staining in the lungs of FVB/N-Tg(teto-Kras2)12Hev mice that 
were treated with doxycycline for 8 weeks and continued with CO treatment for the following 5 
weeks. The number of nodules in the lung cross-sections was evaluated in at least n=5-6 per 
animal. The representative sections and immunohistochemistry with antibody against Ki-67 are 
shown in F. Data are representative for Air n=8, CO n=9 animals. P<0.0002. Scale bar, 200 μm.  
 
Figure 6. Effects of CO on Mitochondria in PCa cells  A. OCR and ECAR were measured in 
PC3 cells treated with medium bubbled with 250 ppm CO. Relative mitochondria activity was 
measured over time and the levels are shown at 30 min. B. OCR was measured in PC3 or 
PNT1A ± Rotenone (20 nM) for 10 min followed by 30 min ± CO (250 ppm).  Data are 
representative for 2 independent experiments in duplicates. C. The levels of glucose and lactate 
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were measured in the lysates of PC3 cells ± CO (250ppm) for 6 hours. D-E. Mitochondrial 
superoxide production was measured by Flow Cytometry using MitoSox. Data are 
representative for 3 independent experiments in triplicates. **p<0.01. F. Cell cycle analysis was 
performed in PC3 and PNT1A cells by PI staining. Cells were synchronized for 48 h via serum-
starvation and then treated for 48h with FBS-containing medium ± CO. Data are representative 
of 3 independent experiments in triplicates. **p<0.01. G. SPECT analysis in PC3 cells ± CO 
(250 ppm) or CORM-A1 (20 or 100 μM) for 24h. Intensity of radiation is presented as a mean ± 
SD of 2 independent experiments performed in triplicate. *p<0.05 vs control, **p<0.01 vs 
control. H. Immunohistochemical staining for cytochrome C in subcutaneous prostate cancer 
xenografts as an indicator of cell death. Representative sections from n=3-4 animals are shown. 
Scale bar, 150 μm. I-J. MitoTracker Red CMXRos staining of PC3 cells treated with 
Doxorubicin (Dox) ± CO for 4h. Hoechst was used to stain nuclei. Representative pictures are 
shown in C and densitometric intensity analyses of 3 fields is shown in D. Results represent 
mean ± SD of 3 independent experiments. *p<0.001 vs control. Scale bar, 10 μm. K. 
Immunoblotting with antibodies against mtTFA in the lysates of CO treated PC3 and A549 cells 
(4h, 250 ppm). L. Immunofluorescence staining with antibody against vimentin in lung 
adenocarcinoma cell line A549, control and Rhoo (EtBr) ± CO (250 ppm, 48h). Data are 
representative of 2 independent experiments in duplicate. Scale bar, 30 μm.  
 
 






